Follow Us
https://www.thebody.com/author/coverage-provided-kent-sepkowitz

Latest by Kent Sepkowitz, M.D.

ACTG 364: Virologic Efficacy of Nelfinavir (NFV) and/or Efavirenz (EFZ) in Combination with New Nucleoside Analogs in Nucleoside Experienced Subjects

Scott Hammer presented data from ACTG 364, a "rollover" study from an earlier NIH trial. This is a Phase II, randomized, trial designed for nucleoside reverse transcriptase inhibitor (NRTI) experienced patients. There were three treatment arms compar...

News

A Phase I Study of Hydroxyurea in HIV-Infected Children Receiving Didanosine and/or Stavudine

This study, conducted by M. Kline and colleagues at Baylor College of Medicine, evaluated the safety, antiviral and immunologic effects, and pharmacokinetics of hydroxyurea, given with ddI and/or d4T to symptomatic HIV-infected children. It is among ...

Antiretroviral Therapy: New Agents and Treatment Naive Patient Populations

Reports on several new compounds addressed the growing need to develop drugs with little cross-resistance to the currently available products. Studies focusing on novel agents in the protease class (AG-1776, poster #11 and ABT-378, poster #15) and NN...

News

Session 84, Abstract 661: A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count 3

In this study by Fisher, et al., 137 treatment-naïve patients with fewer than 500 T-cells were randomized to receive either d4T+ddI or AZT+ddI to determine tolerability and antiretroviral effect. The poster presented in Chicago showed data on 112 pat...

News

Advances Made Towards Simpler Protease Inhibitor Regimens

Poster session abstracts 374 and 393 Promoting adherence to difficult combination drug regimens continues to be a major concern of both doctors and patients. The conference had several presentations on simpler dosing schedules that show promise, but...

News

Antiviral Activity and Acceptance of Two Different Triple Combinations

d4T + Indinavir + 3TC Vs d4T + Indinavir + ddI In this study by a Spanish research group led by N. Villalba, 96 AZT-experienced patients with fewer than 350 CD4 cells/mm3 received standard doses of the nucleoside analog d4T in combination with the p...

News

Antiretroviral Therapy: Unique Adverse Effects of Protease Inhibitors

Endocrinopathies in patients receiving HAART Poster session abstracts 407 - 416 6 reports described a syndrome of fat redistribution variably called "multiple symmetrical lipomatosis," "protease paunch," "buffalo" or "cervical hump," and "periphera...

News

Session 50, Abstract 379: Combination Therapy with AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients with Less than 200 CD4/mm3

In this non-randomized study, Dr. Rubio and colleagues looked at the efficacy and tolerance of combination therapy with AZT + 3TC + indinavir as compared to d4T + 3TC + indinavir. They enrolled forty-four pre-treated patients (either AZT and/or ddI a...

Antiretroviral Therapy: Salvage Regimens

Poster session abstracts 419 - 428 Management of a failing regimen was addressed by numerous investigators. An assortment of approaches was tried, including one in which SIX antiviral drugs were given. Deeks (poster 419) reported on a large communi...